Within 4 months of enzalutamide initiation, four patients (1.1%) had at least one confirmed seizure; three additional patients (0.8%) experienced a seizure within four months following the 4-month study period.
After a pregnancy with eclampsia, a future seizure disorder was significantly more likely (4.58/10,000 person-years) compared with a pregnancy without a hypertensive disorder of pregnancy (0.72/10,000 person-years; crude hazard ratio [HR], 6.09).
"Additional research is needed to evaluate the potential role of medical cannabinoids in children and adolescents, especially given increasing accessibility from state legalization," write the authors.
The system includes a detect-and-respond mode, which is designed to prevent seizures before they start and deliver therapy to stop them if they do.
Results showed that bupropion users were more likely to have a seizure, have accompanied tachycardia on presentation, and be admitted to the hospital, compared to those who ingested a TCA.
The sNDA submitted to support the monotherapy indication included clinical data involving over 2,400 adults with partial-onset seizures.
The efficacy and safety of Aptiom as monotherapy and adjunct therapy for adults with POS was previously established in 5 multicenter, randomized, controlled studies. This data also supported the safety and tolerability of Aptiom for the treatment of pediatric patients with POS.
Increases in the number of persons with active epilepsy were indicated based on National Health Interview Survey data from 2010 to 2015, probably due to population growth.
The researchers observed significant increases in topiramate, rufinamide, and N-desmethylclobazam and a significant decrease in clobazam serum levels with increasing cannabidiol dose.
The researchers found that for individuals with partial seizures, levetiracetam performed statistically significantly better than carbamazepine and lamotrigine for time to withdrawal of allocated treatment.
Potiga, a potassium channel opener, was approved in 2011 as an adjunctive treatment for partial-onset seizures in patients with inadequate response to alternative treatments.
Study patients reported a 50% reduction in seizure severity as well as an improvement in mood among 49% of patients. Improvements in memory and achievement were seen in 38% and 39% of patient, respectively. Moreover, patients reported a 64% reduction in seizure worry.
The researchers found that the serum concentrations of carbamazepine, lamotrigine, levetiracetam, topiramate, and valproic acid decreased after the dietary therapies.
The data showed a reduction in the median frequency of convulsive seizure per month from 12.4 to 5.9 with cannabidiol vs. a reduction from 14.9 to 14.1 with placebo.
A 45-year-old man with a past history of IV drug use was found to be insufflating bupropion at his rehabilitation facility.
The sNDA submission includes data from five controlled clinical trials in adults with POS and three clinical studies demonstrating safety and tolerability in pediatric patients.
The C.O. Truxton product is packaged in 100- or 1000-count bottles in the following strengths: 15mg, 30mg, 60mg, and 100mg.
Proximagen announced promising data from the pivotal Phase 3 trial of USL261 (intranasal midazolam) for the rescue treatment of seizure clusters. The primary efficacy endpoint was treatment success, defined as achieving 1) termination of seizure(s) and 2) no recurrence of seizure(s)
The greatest risk factor for SUDEP was found to be generalized tonic-clonic seizures (GTCS), with a higher frequency of these types of seizures correlating to an increased risk of death.
The mislabeled drug could lead to a potential overdose for patients or their pet(s), resulting in severe intoxication, cardiogenic shock, renal failure, coma or death.